FK506 reduces amyloid plaque burden and induces MMP-9 in AβPP/PS1 double transgenic mice

Journal of Alzheimer's Disease

Volumn 22, Issue 1, 2010, Pages 97-105

  Hong, Hyun Seok ^a   Hwang, Ji Yeon ^a   Son, Sung Min ^a   Kim, Yoon Hee ^a   Moon, Minho ^a   Inhee, Mook Jung ^a  

^a Seoul National University   (South Korea)

Author keywords

Alzheimer's disease; amyloid ; A PP PS1 double transgenic mouse; calcineurin; FK506; MMP 9

Indexed keywords

AMYLOID BETA PROTEIN; CALCINEURIN; GELATINASE B; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; TACROLIMUS;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC ANIMAL;

EID: 78650668291     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100261     Document Type: Article

References (51)

1. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
2. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy Physiol Rev 81, 741-766.
3. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, A23-31.
4. Van Gassen G, Annaert W (2003) Amyloid, presenilins, and Alzheimer's disease. Neuroscientist 9, 117-126.
5. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK (1999) Impaired synap-tic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2, 271-276.
6. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8, 1051-1058.
7. Chen QS, Kagan BL, Hirakura Y, Xie CW (2000) Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 60, 65-72.
8. Rowan MJ, Klyubin I, Wang Q, Anwyl R (2004) Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. Exp Gerontol 39, 1661-1667.
9. Morris RG, Moser EI, Riedel G, Martin SJ, Sandin J, Day M, O'Carroll C (2003) Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Philos Trans R Soc Lond B Biol Sci 358, 773-786.
10. Disterhoft JF, Moyer JR, Jr., Thompson LT (1994) The calcium rationale in aging and Alzheimer's disease. Evidence from an animal model of normal aging. Ann N Y Acad Sci 747, 382-406.
11. Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK (2005) Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 20, 187-198.
12. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ (2008) Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59, 214-225.
13. Arispe N, Pollard HB, Rojas E (1994) beta-Amyloid Ca(2+)-channel hypothesis for neuronal death in Alzheimer disease. Mol CellBiochem 140, 119-125.
14. Kawahara M, Kuroda Y (2000) Molecular mechanism of neu-rodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res Bull 53, 389-397.
15. Ekinci FJ, Linsley MD, Shea TB (2000) Beta-amyloid-induced calcium influx induces apoptosis in culture by oxidative stress rather than tau phosphorylation. Brain Res Mol Brain Res 76, 389-395.
16. MacManus A, Ramsden M, Murray M, Henderson Z, Pearson HA, Campbell VA (2000) Enhancement of (45)Ca(2+) influx and voltage-dependent Ca(2+) channel activity by beta-amyloid-β1-40) in rat cortical synaptosomes and cultured cortical neurons. Modulation by the proinflammatory cytokine interleukin-1beta. J Biol Chem 275, 4713-4718.
17. Mansuy IM (2003) Calcineurin in memory and bidirectional plasticity. Biochem Biophys Res Commun 311, 1195-1208.
18. Crabtree GR, Olson EN (2002) NFAT signaling: choreographing the social lives of cells. Cell 109 Suppl, S67-79.
19. Dawson TM, Steiner JP, Lyons WE, Fotuhi M, Blue M, Snyder SH (1994) The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. Neuroscience 62, 569-580.
20. Matsuda T, Takuma K, Asano S, Kishida Y, Nakamura H, Mori K, Maeda S, Baba A (1998) Involvement of calcineurin in Ca2+ paradox-like injury of cultured rat astrocytes. J Neurochem 70, 2004-2011.
21. Springer JE, Azbill RD, Nottingham SA, Kennedy SE (2000) Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury. J Neurosci 20, 7246-7251.
22. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC (1999) Ca2+-induced apoptosis through calcineurin dephosphoryla-tion of BAD. Science 284, 339-343.
23. Norris CM, Kadish I, Blalock EM, Chen KC, Thibault V, Porter NM, Landfield PW, Kraner SD (2005) Calcineurin triggers reactive/inflammatory processes in astrocytes and is up-regulated in aging and Alzheimer's models. J Neurosci 25, 4649-4658.
24. Kaminuma O (2008) Selective inhibitors of nuclear factor of activated T cells: potential therapeutic drugs for the treatment of immunological and inflammatory diseases. Inflamm Allergy Drug Targets 7, 35-40.
25. Cardoso SM, Oliveira CR (2005) The role of calcineurin in amyloid-beta-peptides-mediated cell death. Brain Res 1050, 1-7.
26. Dineley KT, Hogan D, Zhang WR, Taglialatela G (2007) Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem 88, 217-224.
27. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17, 157-165.
28. Butcher SP, Henshall DC, Teramura Y, Iwasaki K, Sharkey J (1997) Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci 17, 6939-6946.
29. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neu-robiolDis 18, 602-617.
30. Kochi S, Takanaga H, Matsuo H, Naito M, Tsuruo T, Sawada Y (1999) Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. Eur J Pharmacol 372, 287-295.
31. Taglialatela G, Hogan D, Zhang WR, Dineley KT (2009) Intermediate-and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav Brain Res 200, 95-99.
32. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM (2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 281, 2456624574.
33. Deb S, Wenjun Zhang J, Gottschall PE (2003) Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res 970, 205-213.
34. Arendt T (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118, 167-179.
35. Martyn C (2003) Anti-inflammatory drugs and Alzheimer's disease. BMJ 327, 353-354.
36. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mTOR, A{beta} and tau: Effects on cognitive impairments. J Biol Chem 285, 1310713120.
37. Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO (2009) The role of neuroimmunomodulation in Alzheimer's disease. Ann NY Acad Sci 1153, 240-246.
38. James JA, Jamal S, Hull PS, Macfarlane TV, Campbell BA, Johnson RW, Short CD (2001) Tacrolimus is not associated with gingival overgrowth in renal transplant patients. J Clin Periodontol 28, 848-852.
39. Hohage H, Hillebrandt U, Welling U, Zeh M, Heck M, Ger-hardt UW, Suwelack BM (2005) Cyclosporine and tacrolimus: influence on cardiovascular risk factors. Transplant Proc 37, 1036-1038.
40. Martinez-Martinez S, Redondo JM (2004) Inhibitors of the calcineurin/NFAT pathway. CurrMed Chem 11, 997-1007.
41. Cardenas ME, Zhu D, Heitman J (1995) Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr Opin Nephrol Hypertens 4, 472-477.
42. Ke H, Huai Q (2003) Structures of calcineurin and its complexes with immunophilins-immunosuppressants. Biochem Bio-phys Res Commun 311, 1095-1102.
43. Doller A, Akool el S, Muller R, Gutwein P, Kurowski C, Pfeilschifter J, Eberhardt W (2007) Molecular mechanisms of cyclosporin A inhibition of the cytokine-induced matrix metalloproteinase-9 in glomerular mesangial cells. J Am Soc Nephrol 18, 581-592.
44. Kudryashova IV, Onufriev MV, Kudryashov IE, Gulyaeva NV (2009) Caspase-3 activity in hippocampal slices reflects changes in synaptic plasticity. Neurosci Behav Physiol 39, 1320.
45. Agostinho P, Oliveira CR (2003) Involvement of calcineurin in the neurotoxic effects induced by amyloid-beta and prion peptides. Eur J Neurosci 17, 1189-1196.
46. Louneva N, Cohen JW, Han LY, Talbot K, Wilson RS, Bennett DA, Trojanowski JQ, Arnold SE (2008) Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. Am J Pathol 173, 1488-1495.
47. Love S, Siew LK, Dawbarn D, Wilcock GK, Ben-Shlomo Y, Allen SJ (2006) Premorbid effects of APOE on synaptic proteins in human temporal neocortex. Neurobiol Aging 27, 797-803.
48. Kaminska B, Gaweda-Walerych K, Zawadzka M (2004) Molecular mechanisms of neuroprotective action of immunosuppressants-facts and hypotheses. J Cell Mol Med 8, 45-58.
49. Baran DA, Galin ID, Gass AL (2004) Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment. Am J Cardiovasc Drugs 4, 21-29.
50. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and phar-macodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43, 623-653.
51. Olyaei AJ, de Mattos AM, Bennett WM (2001) Nephrotoxic-ity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 7, 384-389.